Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicaid waivers

Executive Summary

Sen. Snowe (R-Vt.) introduces bill (S 1177) July 12 that would give HHS authority to grant Medicaid demonstration project waivers like those given to Maine and Vermont, in which Medicaid drug prices are offered to residents without drug coverage. The Pharmaceutical Research & Manufacturers of America won its case against the Vermont program in Washington, D.C. federal appeals court and has filed a lawsuit against the Maine program (1"The Pink Sheet" July 9, p. 3). Sens. Collins (R-Maine), Jeffords (I-Vt.) and Leahy (D-Vt.) co-sponsored the bill

You may also be interested in...

Maine Rx Rebate Program Stayed As PhRMA Mulls Supreme Court Case

The Maine Rx Program will be prevented from going into effect until the end of July as the Pharmaceutical Research & Manufacturers of America considers whether it should pursue its case against the program to the U.S. Supreme Court.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts